Eos Advisory’s portfolio has reached a total valuation of £121m off the back of recent investment rounds and its first two exits, including Genus acquiring a large stake in aquaculture firm Xelect.
In January 2021, the St Andrews-based investment firm led a £1.2m investment into RAB-Microfluidics, an Aberdeen-headquartered company developing microfluidic technology to diagnose engine and turbine wear in real time.
The following month, Eos secured its first strategic investment partnership with US-based Kineticos Life Sciences, to co-invest in early stage Scottish companies. They aim to invest over £10m over the next five years in oncology-focused life sciences ventures.
In June, sustainable food protein scale-up Enough - previously called 3F BIO - made $43m in a Series B funding round.
Then in July, RNA and DNA genetic sequencing specialist Wobble Genomics, a spin-out from the University of Edinburgh’s Roslin Institute, secured a £2.15m round led by Eos.
The past year has also been focused on building the Eos team, with the board appointment of Chris Brinsmead, a former senior AstraZeneca executive and former adviser to the UK Government on life sciences, and hiring Callum Keddie, who previously led a London-based venture capital fund, as an investment executive.
The firm now has three investment areas in place: the Eos Syndicate, Eos Innovation Fund, and Eos Venture Partnerships.
Andrew McNeill, managing partner at Eos Advisory, said: “Over the past 12 months, Eos Advisory has seen significant growth both in our portfolio and in our core business.
“We already had a strong track record for due diligence and supporting our portfolio, but we have found that better communicating our focus and process as impact investors has really widened our network of investors and our opportunities.”
“On the investor side, we have expanded the investor base outside Scotland, especially across the UK and North America - 2022 is going to be another exciting year and we have a number of milestone announcements in the pipeline.”
Founded in 2014, Eos has a portfolio of 13 investee companies, including Cumulus Oncology, ILC Therapeutics, and Clinspec DX.
It invests in four key impact areas: disease diagnosis, prevention and treatment; energy security, climate change and pollution; food and water security, and; sustainability of industrial processes and infrastructure.
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
